4-methyl-1-pyridin-3-yl-pentan-3-one | 261711-21-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-methyl-1-pyridin-3-yl-pentan-3-one
• 英文别名: 4-methyl-1-pyridin-3-ylpentan-3-one
• CAS: 261711-21-1
• 化学式: C₁₁H₁₅NO
• 分子量: 177.246
• InChiKey: DNKBXJOJWLOMBG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-methyl-1-pyridin-3-yl-pentan-3-one 在 sodium hydroxide 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 3.33h， 生成 4-hydroxy-6-isopropyl-6-(2-pyridin-3-yl-ethyl)-5,6-dihydro-pyran-2-one
  参考文献：
  名称：

  4-Hydroxy-5,6-dihydropyrones as Inhibitors of HIV Protease:  The Effect of Heterocyclic Substituents at C-6 on Antiviral Potency and Pharmacokinetic Parameters

  摘要：

  Due largely to the emergence of multi-drug-resistant HIV strains, the development of new HIV protease inhibitors remains a high priority for the pharmaceutical industry. Toward this end, we previously identified a 4-hydroxy-5,6-dihydropyrone lead compound (CI-1029, 1) which possesses excellent activity against the protease enzyme, good antiviral efficacy in cellular assays, and promising bioavailability in several animal species. The search for a suitable backup candidate centered on the replacement of the aniline moiety at C-6 with an appropriately substituted heterocyle. In general, this series of heterocyclic inhibitors displayed good activity (in both enzymatic and cellular tests) and-low cellular toxicity; furthermore, several analogues exhibited improved pharmacokinetic parameters in animal models. The compound with the best combination of high potency, low toxicity, and favorable bioavailabilty was (S)-3-(2-tertbutyl-4-hydroxymethy1- 5-methyl-phenylsulfanyl)-4-hydroxy-6-isopropyl-6-(2-thiophen-3-yl-ethyl)-5,6-dihydro-pyran-2-one (13-(S)). This thiophene derivative also exhibited excellent antiviral efficacy against mutant HIV protease and resistant HIV strains. For these reasons, compound 13-(S) was chosen for further preclinical evaluation.

  DOI：

  10.1021/jm0003844
• 作为产物：
  描述：

  3-碘吡啶 、 4-甲基-1-戊烯-3-醇 在 palladium diacetate 、 四丁基氯化铵 、 碳酸氢钠 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 以79%的产率得到4-methyl-1-pyridin-3-yl-pentan-3-one
  参考文献：
  名称：

  4-Hydroxy-5,6-dihydropyrones as Inhibitors of HIV Protease:  The Effect of Heterocyclic Substituents at C-6 on Antiviral Potency and Pharmacokinetic Parameters

  摘要：

  Due largely to the emergence of multi-drug-resistant HIV strains, the development of new HIV protease inhibitors remains a high priority for the pharmaceutical industry. Toward this end, we previously identified a 4-hydroxy-5,6-dihydropyrone lead compound (CI-1029, 1) which possesses excellent activity against the protease enzyme, good antiviral efficacy in cellular assays, and promising bioavailability in several animal species. The search for a suitable backup candidate centered on the replacement of the aniline moiety at C-6 with an appropriately substituted heterocyle. In general, this series of heterocyclic inhibitors displayed good activity (in both enzymatic and cellular tests) and-low cellular toxicity; furthermore, several analogues exhibited improved pharmacokinetic parameters in animal models. The compound with the best combination of high potency, low toxicity, and favorable bioavailabilty was (S)-3-(2-tertbutyl-4-hydroxymethy1- 5-methyl-phenylsulfanyl)-4-hydroxy-6-isopropyl-6-(2-thiophen-3-yl-ethyl)-5,6-dihydro-pyran-2-one (13-(S)). This thiophene derivative also exhibited excellent antiviral efficacy against mutant HIV protease and resistant HIV strains. For these reasons, compound 13-(S) was chosen for further preclinical evaluation.

  DOI：

  10.1021/jm0003844
• 作为试剂：
  描述：

  3-碘吡啶 、 4-甲基-1-戊烯-3-醇 、 碳酸氢钠 、 四氢吡咯 在 四丁基氯化铵 、 醋酸钯 4-methyl-1-pyridin-3-yl-pentan-3-one 、 Ethyl acetate hexane methylene-chloride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-methyl-1-pyridin-3-yl-pentan-3-one
  参考文献：
  名称：

  HIV protease inhibitors

  摘要：

  本发明涉及新型带有异构环的链式二氢吡喃，具有改良的药理学性质，能够强力抑制HIV天冬氨酸蛋白酶，从而阻止HIV的感染性。这些二氢吡喃可用于开发治疗病毒感染和疾病的疗法，包括艾滋病。本发明还涉及制备这些二氢吡喃的合成方法和制备最终化合物的中间体。

  公开号：

  US20050075390A1

文献信息

• CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY
  申请人：Baker William R.

  公开号：US20090318396A1

  公开（公告）日：2009-12-24

  New chemical entities which comprise corticosteroids and phosphorylated β-agonists for use in therapy and compositions comprising and processes for preparing the same.

  新的化学实体包括皮质类固醇和磷酸化的β-激动剂，用于治疗以及包含这些化学实体的组合物和制备它们的方法。
• MCL-1 INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20190352271A1

  公开（公告）日：2019-11-21

  The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

  本公开涉及通常用于治疗癌症的化合物和药物组合物。
• 2,3-DISUBSTITUTED 1 -ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS
  申请人：GLAXOSMITHKLINE INTELECTUAL PROPERTY (NO.2) LIMITED

  公开号：US20160016908A1

  公开（公告）日：2016-01-21

  The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.

  本发明涉及新型化合物、含有这种化合物的制药组合物以及它们在治疗中的应用。
• 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
  申请人：GlaxoSmithKline Intellectual Property (No.2) Limited

  公开号：US10034881B2

  公开（公告）日：2018-07-31

  The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.

  本发明涉及新型化合物、含有此类化合物的药物组合物及其在治疗中的应用。
• MCL-1 inhibitors
  申请人：Gilead Sciences, Inc.

  公开号：US10703733B2

  公开（公告）日：2020-07-07

  The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

  本公开内容一般涉及可用于治疗癌症方法的化合物和药物组合物。